Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
Preprint
- 1 November 2020
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
SUMMARY: Neutralizing antibodies (nAbs) hold promise as effective therapeutics against COVID-19. Here, we describe protein engineering and modular design principles that have led to the development of synthetic bivalent and tetravalent nAbs against SARS-CoV-2. The best nAb targets the host receptor binding site of the viral S-protein and its tetravalent versions can block entry with a potency that exceeds the bivalent nAbs by an order of magnitude. Structural studies show that both the bivalent and tetravalent nAbs can make multivalent interactions with a single S-protein trimer, observations consistent with the avidity and potency of these molecules. Significantly, we show that the tetravalent nAbs show much increased tolerance to potential virus escape mutants. Bivalent and tetravalent nAbs can be produced at large-scale and are as stable and specific as approved antibody drugs. Our results provide a general framework for developing potent antiviral therapies against COVID-19 and related viral threats, and our strategy can be readily applied to any antibody drug currently in development.Keywords
Other Versions
- Published version: Version Journal of Molecular Biology, 433, preprints
This publication has 59 references indexed in Scilit:
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- De novo design of picomolar SARS-CoV-2 miniprotein inhibitorsScience, 2020
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19The New England Journal of Medicine, 2020
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B CellsCell, 2020
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2Cell Host & Microbe, 2020
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 InfectionThe Journal of Immunology, 2020
- Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographsNature Methods, 2019
- Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirusProceedings of the National Academy of Sciences of the United States of America, 2015
- Towards automated crystallographic structure refinement with phenix.refineActa crystallographica. Section D, Structural biology, 2012
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999